EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitLeitlinieOpen Access · CC BY-NC-ND 4.0

EAA/EMQN best practice guidelines for molecular diagnosis of Y‐chromosomal microdeletions: State of the art 2023

Csilla Krausz iD, Paulo Navarro-Costa iD, Martina Wilke iD, Frank Tüttelmann iD

Andrology · 2024-03 · 12 (3) · 487-504

DOI: 10.1111/andr.13514 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Andrology, online erschienen am 06.09.2023. Verfasst von Csilla Krausz und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, University Hospital Careggi, Florence, Italy. Hauptthemen laut MEDLINE: Andrology, Infertility, Male, Azoospermia, Oligospermia. Die Arbeit wurde bisher 79-mal zitiert (Crossref) und nennt 136 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Fundação para a Ciência e a Tecnologia, European Cooperation in Science and Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Testing for AZoospermia Factor (AZF) deletions of the Y chromosome is a key component of the diagnostic workup of azoospermic and severely oligozoospermic men. This revision of the 2013 European Academy of Andrology (EAA) and EMQN CIC (previously known as the European Molecular Genetics Quality Network) laboratory guidelines summarizes recent clinically relevant advances and provides an update on the results of the external quality assessment program jointly offered by both organizations. A basic multiplex PCR reaction followed by a deletion extension analysis remains the gold‐standard methodology to detect and correctly interpret AZF deletions. Recent data have led to an update of the sY84 reverse primer sequence, as well as to a refinement of what were previously considered as interchangeable border markers for AZFa and AZFb deletion breakpoints. More specifically, sY83 and sY143 are no longer recommended for the deletion extension analysis, leaving sY1064 and sY1192, respectively, as first‐choice markers. Despite the transition, currently underway in several countries, toward a diagnosis based on certified kits, it should be noted that many of these commercial products are not recommended due to an unnecessarily high number of tested markers, and none of those currently available are, to the best of our knowledge, in accordance with the new first‐choice markers for the deletion extension analysis. The gr/gr partial AZFc deletion remains a population‐specific risk factor for impaired sperm production and a predisposing factor for testicular germ cell tumors. Testing for this deletion type is, as before, left at the discretion of the diagnostic labs and referring clinicians. Annual participation in an external quality control program is strongly encouraged, as the 22‐year experience of the EMQN/EAA scheme clearly demonstrates a steep decline in diagnostic errors and an improvement in reporting practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AndrologyInfertility, MaleAzoospermiaOligospermiaSertoli Cell-Only SyndromeSex Chromosome AberrationsSex Chromosome Disorders of Sex DevelopmentHumansMaleSemenChromosome DeletionChromosomes, Human, YMultiplex Polymerase Chain Reaction

Stichwörter der Autor:innen

AZFY chromosome microdeletionazoospermiagr/gr deletionhuman geneticsmale infertilityoligozoospermiaquality controlspermatogenesis

Autor:innen und Institutionen

  • Department of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, University Hospital Careggi, Florence, Italy.
  • EvoReproMed Lab, Environmental Health Institute (ISAMB), Associate Laboratory TERRA, Faculty of Medicine, University of Lisbon, Lisbon, Portugal.
  • Gulbenkian Science Institute, Oeiras, Portugal.
  • Department of Clinical Genetics, Erasmus MC, Rotterdam, The Netherlands.
  • Institute of Reproductive Genetics, University of Münster, Münster, Germany.

ORCID-Profile: Csilla Krausz, Paulo Navarro-Costa, Martina Wilke, Frank Tüttelmann

Förderung

  • Fundação para a Ciência e a Tecnologia
  • European Cooperation in Science and Technology

Zitieren

APA

Krausz, C., Navarro-Costa, P., Wilke, M., & Tüttelmann, F. (2024). EAA/EMQN best practice guidelines for molecular diagnosis of Y‐chromosomal microdeletions: State of the art 2023. Andrology, 12(3), 487-504. https://doi.org/10.1111/andr.13514

Vancouver

Krausz C, Navarro-Costa P, Wilke M, Tüttelmann F. EAA/EMQN best practice guidelines for molecular diagnosis of Y‐chromosomal microdeletions: State of the art 2023. Andrology. 2024;12(3):487-504. doi:10.1111/andr.13514

BibTeX
@article{Krausz2024,
  author = {Krausz, Csilla and Navarro-Costa, Paulo and Wilke, Martina and Tüttelmann, Frank},
  title = {EAA/EMQN best practice guidelines for molecular diagnosis of Y‐chromosomal microdeletions: State of the art 2023},
  journal = {Andrology},
  year = {2024},
  volume = {12},
  number = {3},
  pages = {487--504},
  doi = {10.1111/andr.13514}
}
Kostenlos starten →